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Abstract
One difficult question facing researchers is how to prioritize SNPs detected from genetic association studies for functional
studies. Often a list of the top M SNPs is determined based on solely the p-value from an association analysis, where M is
determined by financial/time constraints. For many studies of complex diseases, multiple analyses have been completed
and integrating these multiple sets of results may be difficult. One may also wish to incorporate biological knowledge, such
as whether the SNP is in the exon of a gene or a regulatory region, into the selection of markers to follow-up. In this
manuscript, we propose a Bayesian latent variable model (BLVM) for incorporating ‘‘features’’ about a SNP to estimate a
latent ‘‘quality score’’, with SNPs prioritized based on the posterior probability distribution of the rankings of these quality
scores. We illustrate the method using data from an ovarian cancer genome-wide association study (GWAS). In addition to
the application of the BLVM to the ovarian GWAS, we applied the BLVM to simulated data which mimics the setting
involving the prioritization of markers across multiple GWAS for related diseases/traits. The top ranked SNP by BLVM for the
ovarian GWAS, ranked 2
nd and 7
th based on p-values from analyses of all invasive and invasive serous cases. The top SNP
based on serous case analysis p-value (which ranked 197
th for invasive case analysis), was ranked 8
th based on the posterior
probability of being in the top 5 markers (0.13). In summary, the application of the BLVM allows for the systematic
integration of multiple SNP ‘‘features’’ for the prioritization of loci for fine-mapping or functional studies, taking into account
the uncertainty in ranking.
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Introduction
Many genome-wide association studies of complex diseases and
phenotypes have been completed in the last decade [1]. Since
these only identify the general locus for the risk allele, rigorous and
robust methods are needed to select which chromosomal regions
should be prioritized for follow-up fine-mapping and/or functional
studies. Often a list of the top M SNPs is determined based on the
p-value from the association analysis and carried forward into the
next stage of the study, where M is determined by financial
constraints. However, this approach is not optimal as rankings are
very variable (i.e., variance in the sampling distribution of rankings
can be large) and the ‘‘causative’’ variant may not be at the top of
ranked order of SNPs [2,3]. In addition, for many studies of
complex diseases, multiple analyses have been completed (e.g.,
multiple related diseases/phenotypes or subtypes of disease) and
integrating these multiple sets of results may be challenging. One
may also wish to incorporate biological knowledge, such as
whether the SNP is in the exon of a gene or a regulatory region,
into the selection of markers to follow-up.
Alternative approaches, that do not prioritize for follow-up
based only on ranked p-values, are based on statistical models in
which prior knowledge about the SNP can be incorporated into
the association analysis, using hierarchical, mixed, or multi-level
models [4,5,6,7,8,9]. Chen and Witte [9] describe a mixed model
framework for modeling M SNPs together where the SNP effects
are modeled with both the mean and variance of the multivariate
normal distribution depending on prior information. Bayesian
analysis of case-control studies using power priors to incorporate
historical knowledge was proposed by Cheng and Chen [10],
while Lewinger et al [11] proposed a hierarchical Bayes method of
weighting single SNP association results in a prior model that
incorporates previous knowledge.
In this manuscript, we present a Bayesian latent variable model
(BLVM) [12,13], similar to methods used to rank academic
institutions and hospitals [14], for the prioritization of markers for
follow-up in future replication or functional studies. The BLVM
allows for the incorporation of any type of observed information or
‘‘features’’ about a SNP (e.g., p-value, effect size, functional
variant, minor allele frequency, published association in the peer-
reviewed literature) into a model in which a latent ‘‘quality score’’
is estimated for each SNP. A drawback of other prioritization/
ranking approaches is that they do not incorporate the uncertainty
of the ranking into the prioritization [3]. Therefore, we propose
the prioritization of SNPs to follow-up based on the posterior
distribution of the rankings of the latent SNP quality scores [15].
We illustrate the BLVM for prioritization of SNPs for follow-up
using data from an ovarian cancer GWAS of 1815 invasive
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addition to the application of the method to the ovarian GWAS,
where we do not know the ‘‘truth’’, we apply the BLVM to
simulated data, in which we know the truth. The simulated data
mimics the setting in which four independent studies have been
conducted for four related diseases/traits (e.g., inflammation-
related diseases, cancers involving solid tumors) with the
incorporation of where or not the marker is non-synonymous
(amino-acid changing) coding into the prioritization.
Methods
General Formulation of the Bayesian Latent Variable
Model (BLVM)
For K SNPs in the association analysis, let hk,k = 1 ,… ,K
represent the latent ‘‘quality score’’ for each SNP. We wish to
estimate the latent variables hk based on a set of observed features
for the SNP, with Xkj representing the j
th observed feature for the
k
th SNP. Some possible features may included: 2log10(p-value),
effect size, minor allele frequency (MAF), function of SNP,
previously reported SNP or in a pathway or interest. A model is
then specified to associate the features with the latent variables.
One possible (simple) model is as follows: Xkj~bjzljhkzukj,
j=1, …J features, k=1, …K SNPs where Xkj represents the value
for the j
th continuous feature for the k
th SNP, hk represents the
latent ‘‘quality score’’ for SNP k, lj represents the importance of
the feature (i.e., how well this feature distinguishes between SNPs),
and ukj are the random errors and ukj*N(0,t2
j ) [12,14]. A
graphical depiction of a simplified model is presented in Figure 1.
In the case that the feature is binary, there are a few options: a
latent probit model could be utilized [16], such that Xkj*Ber(pkj)
with pkj~P(Ykjw0) and Ykj*N(gkj,1); a logistic model
Xkj*Ber(pkj) with log pkj
.
1-pkj
  
~bjzljhk [17,18].
To complete the model specification, prior distributions are
then placed on all parameters in the model. To ensure proper
posterior distributions, proper prior distributions, as opposed to
improper prior distributions, are placed on all parameters in the
model [19]. The prior distributions for the latent scores hi are
typically taken to be independent standard normal distributions,
N(0,1). To ensure unique labeling, one can impose strong or
constraint priors for a few of the lj [12]. For example, if it is
deemed essential to have a high value of feature to correspond to a
high quality score, one could restrict the prior distribution to be a
normal distribution censored at 0 (i.e., l*N(0,1)I½0,?)). In the
case of latent variable models for SNPs, one may also want to
model the dependency between the SNPs and their corresponding
quality scores by using a prior for h that is multivariate normal,
such as h~(h1,:::,hK)
T*MVN(m,V) with m*MVN(0,S) and
V-1*Wishart(R,u), with the matrices S and R are fixed (e.g.,
R=diagonal matrix consisting of 1). Another choice for modeling
the dependency in the SNP quality scores would be to model the
dependency between the latent SNP quality scores as a function of
LD or spatial distance [8], such as h*MVN(0,S(a2,w)), where
Sij(s2,w)~s2exp(-dij=w) is the covariance between quality scores
for SNPs i and j with dij representing the distance between the two
SNPs (e.g., Euclidean distance between the locations of the two
SNPs).
Genome-wide study of ovarian cancer
Ovarian cancer is the fourth leading cause of cancer death
among women in the United States. In 2009, it is estimated that
21,550 new cases will be diagnosed in the United States, and
14,600 women will die from the disease [20]. Ovarian cancer risk
sharply increases after the age of 40 years and peaks between 65
and 79 years [20]. In the United States, white non-Hispanic
women have approximately 40% higher rates of ovarian cancer
than Hispanic or African-American women [20]. Most patients
are diagnosed with advanced disease because of the lack of an
effective screening strategy and the non-specific nature of early
signs and symptoms associated with this disease. For the
approximate 25% of women who are diagnosed with disease
confined to the ovary or ovaries, five-year survival rates are high
(75%–90%). For the 75% of women diagnosed with stage III and
IV disease, however, the likelihood of long term disease-free
survival is low (15%–20%).
The ovarian cases from the US GWAS that will be used for
illustration of the latent variable model for ranking SNPs includes
four North American studies: (1) FOTS, a population-based study
from Ontario 1995–1999, (2) MAYO, a clinic-based study of cases
and matched controls in the American upper Midwest 1999–2007,
(3) NCOCS, a case-control study covering 48 counties in North
Carolina, and (4) TBOCS, a population-based study conducted in
Tampa, Florida. The study protocol was approved by the
institutional review board at each center (Duke University
Institutional Review Board, Mayo Clinic Institutional Review
Board, Moffitt Cancer Center Institutional Review Board,
Women’s College Research Institute Institutional Review Board),
and all study participants provided written informed consent.
Eligibility for cases is confirmed epithelial ovarian cancer (tubal,
primary peritoneal, germ cell, stromal, and unknown histology are
excluded) with invasive disease (cases with low malignant potential
are excluded). Eligible controls are matched within each study to
cases on age, race and residence. All cases and controls were
additionally required to have adequate DNA, no prior history
colorectal cancer at age less than 50, and no prior history of
ovarian, breast, endometrioid cancer; in addition, known non-
Caucasian, Jewish, Hispanic, and related participants were
excluded. After all samples were genotyped using the Illumina
Infinium Human610-Quad BeadChip and quality control had
been completed, a total of 1,815 ovarian cancer cases (1,070
invasive serous ovarian cancer) and 1,900 controls were available
for association analysis.
Analysis for association of genetic markers with cancer status (all
invasive ovarian cancer cases versus controls), along with subtype
analysis of invasive serous ovarian cancer cases versus controls,
was completed using PLINK software [21]. Results from a
randomly selected chromosome (chromosome 20) were utilized to
illustrate the use of the latent variable model in prioritizing SNPs
for follow-up in functional studies (accounting for the uncertainty
in the ranking).
Figure 1. Diagram of Latent Variable Model.
doi:10.1371/journal.pone.0020764.g001
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Below, we outline five specific latent variable models for the
ranking of SNPs which were applied to the ovarian cancer GWAS.
The five BLVMs for prioritization of SNPs involve the following
SNP ‘‘features’’: Minor allele frequency (MAF), p-value and odds
ratio (OR) from analysis involving all cases and p-value and OR
from analysis involving a subset of the cases (i.e., histological
subtype). All features were first transformed such that ‘‘large’’
values of the factor would result in a ‘‘large’’ SNP quality score. In
addition, transformations for the various features were selected
such that they could be modeled using a normal distribution (for
speed in computation of the MCMC). It should be noted that
additional SNP features could be included in the model, such as,
whether or not the SNP is a non-synonymous coding variant or
associated with mRNA expression (eSNP) [22,23]. Likewise, a
variety of transformations of the features could also be employed.
For our presentation of the BLVM, we chose the following
transformations for the SNP features: f(p-value)=2logit(p-value),
g(MAF)=logit(2*MAF), h(OR)=log(OR) if OR.1 and log(1/OR)
if OR,1. The transformation selected for the odds ratios resulted
in making the effects all in same direction (‘‘risk’’) with the log
transformation allowing h(OR) to be modelled with a normal
distribution censored at 0. Since MAF is between 0 and 0.5, we
double the MAF to get a value that ranged between 0 and 1 for the
logit transformation that allowed for modeling g(MAF) with a
normal distribution. Lastly, we chose to transform the p-values
using the minus logit with subsequent modeling of f(p-value) with a
normal distribution. These transformations also allow use of set
constraints on the latent variable model to allow for identifiability
of the model parameters, with large values for features (f(p-value),
g(MAF) and h(OR)) indicating larger SNP quality scores.
Model 1 involves J=5 features including p-values and effect sizes
for two analysis along with the minor allele frequency for K SNPs,
assuming the J features and K SNP quality scores are independent.
First, we specify the likelihood model for the J=5 features as
h(OR:1k)~b1zl1hkzu1k with u1k*N(0,t2
1)I(0,?), h(OR:2k)
~b2zl2hkzu2k with u2k*N(0,t2
2)I(0,?), f(p-value:1k)
~b3zl3hkzu3k with u3k*N(0,t2
3), f(p-value:2k)~b4zl4hk
zu4k with u4k*N(0,t2
4),a n dg(MAFk)~b5zl5hkzu5k with
u5k*N(0,t2
5),w h e r eN(m,t2)I(0,?) indicates left censored normal
distribution at 0 and hk represents the latent ‘‘quality score’’ for SNP
k.Next,wespecifypriordistributionsfortheparametersinthemodel.
For latent variable models, the direction for the latent variables is
arbitrary and without constraints on some of the parameters one can
encounter what is referred to as ‘‘labeling issues’’ or ‘‘sign changes’’
[24]. Thus, to ensure unique labeling, we have chosen to impose
strong priors on the parameters lj such that the higher the value of
the feature the higher the SNP quality score (e.g., SNPs with high
values for f(p-value) will have a higher quality score than those SNPs
with low values for f (p-value)). The prior model is specified as
hk*N(0,1) for k=1,…,K, lj*N(0,10)I(0,?), bj*N(0,10) and
1=t2
j *Gamma(0:01,0:01) for j=1,…,5. It should be noted that
when only one of the lj had a strong prior distribution specified to
help ensure labeling (i.e., l1*N(0,10)I(0,?)), with the remaining
parameters having prior distribution unrestricted (lj*N(0,10),
j=1), the MCMC failed to converge (as assessed by convergence
statistics and trace plots) due to ‘‘labeling’’ issues [25].
The second model we investigated (Model 2) was similar to
Model 1. However, the odds ratio features were removed leaving
only the p-values and MAF features in the model. The rationale
for removing the effect sizes from the BLVM was that on
observations, it appeared that too much weight might be given to
SNPs with very low MAF, as these are the markers that often have
the larger effect sizes (but larger standard errors). The third model
(Model 3) explored was one that was the similar to Model 2 (only
p-values and MAF features included) but with the latent quality
scores assumed to be dependent and model with the conjugate
multivariate Normal – Wishart prior. That is, we model the latent
SNP quality scores as h~(h1,:::,hK)
T*MVN(m,V) with
m*MVN(0,S) and V-1*Wishart(R,u), with the matrices
S~100|I, R~0:10|I and u=K where I is a K6K identity
matrix. In contrast to modeling the dependency in the latent SNP
quality scores, in Model 4 we model dependency between the
parameters bj. That is, Model 4 is identical to Model 2 but
with the bj’s modeled as (b1,:::,bJ)
T*MVN(mb,Vb) with
mb*MVN(0,Sb) and V-1
b *Wishart(Rb,J), with the matrices
Sb~100|I, Rb~0:10|I and where I is a J6J identity matrix.
The final model investigated (Model 5) was again similar to
Model 2 but with fewer constraints for identifiability, with only
constraints placed on the parameters lj for the p-value features
and not the MAF feature.
The BLVM can be fit and parameters estimated within a
Markov chain Monte Carlo. For application of the BLVM to
prioritization of SNPs, we are mostly concerned with the latent
SNP ‘‘quality scores’’, hk and not the parameters lj and bj.I n
addition to parameter estimation for hk, we are also concerned
with the relative ranking of the SNPs, along with the incorporation
of uncertainty in the rankings. For example, we can estimate the
probability that a given SNP will be in the top 5 based on the
posterior distribution of the rankings to aid in the prioritizing of
SNPs for follow-up functional or fine-mapping studies. A benefit of
completing the latent variable modeling within a Bayesian
formulation is the flexibly of model form and the ability to assess
model fit. Various models can be fit and to assess the robustness of
the findings. For example, instead of assuming normality of the
quality scores hk, we could assume the scores follow a heavier
tailed distribution (e.g., t-distribution).
Simulated data
To illustrate the use of the BLVM for the prioritization of SNPs
from multiple GWAS studies along with the incorporation of
functional information for the variants, we simulated 10 replicate
sets of results (e.g., p-values for single SNP association) for 100
markers and four disease phenotypes (e.g., ovarian cancer, breast
cancer, prostate cancer, pancreatic cancer) for four scenarios. The
objective of the application of the BLVM is to determine possible
genetic variants relevant with the four phenotypes that should be
prioritized for functional studies. In simulating the SNP association
p-values, we treated markers 10, 20 and 40 as non-synonymous
coding variants, with the remaining markers considered ‘‘non-
coding’’ variants. Scenario 1 represents the case in which none of
the markers was associated with the phenotypes (e.g., null). The
second and third scenarios involving markers being associated with
the first two disease phenotypes; marker 10 (coding SNP)
associated in scenario 2 and marker 60 (non-coding SNP)
associated in scenario 3. The last scenario involved the setting in
which marker 60 was associated with all four disease phenotypes.
The 100 p-values for the four association studies were simulated,
assuming independence, from a Uniform(0,1) distribution for the
case of a ‘‘null’’ SNP association and from a Uniform(0, 0.05)
distribution for the case of a ‘‘non-null’’ SNP association.
Specific latent models applied to simulated data
As outlined for the BLVM for the ovarian GWAS, we chose to
transform the four p-values for association for each SNP using f(p-
value)=2logit(p-value). We coded the functional feature of the k
th
SNP as Ck=1 if coding SNP and Ck=0 if non-coding SNP. The
model we applied to the simulated data (Model 6) involved J=5
Ranking SNPs and Loci for Follow-Up Studies
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modeling all SNP features and quality scores as independent. Let
f(p-value:Dk)~bDzlDhkzuDk with uDk*N(0,t2
D),D = 1 ,2 ,
3, 4 and Ck*Ber(pk) with log(pk=1-pk)~b5zl5hk where hk
represents the latent ‘‘quality score’’ for SNP k. The prior model is
specified as hk*N(0,1) for k=1,…,100, lj*N(0,10)I(0,?),
bj*N(0,10) and 1=t2
j *Gamma(0:01,0:01) for j=1,…,5. The
amount of weight given to each feature is similar, with each feature
effect having a normal distribution with mean 0 and variance 10,
censored at 0. To give less to the coding feature, a smaller variance
could be used in specifying the coding feature prior
(lj*N(0,1)I(0,?)), which would results in shrinkage of this effect
(and importance) towards zero.
Results
Genome-wide study of ovarian cancer
Comparison of five latent models. T h ef i v ed i f f e r e n tl a t e n t
variable models outlined above were first assessed using the top 100
SNPs on chromosome 20 from the ovarian GWAS. All five models
were fit using the WinBUGS software package [26] by way of the R
package BRugs [27]. For each analysis, three independent chains
were run, each with 40,000 iterations, with the first 20,000 removed
for burn-in of the MCMC. Convergence was checked using trace
plots and the
ﬃﬃﬃﬃ
R
p
measure discussed by Gelman et al [25].
Figure 2 shows the relationship between the estimated rank
(mean of the posterior distribution for the rank of the latent SNP
quality score) and the 2log10(p-values) for the case-control analysis
using all cases (Figure 2A) and the subset of cases with serous
histology (Figure 2B). Figure 3 displays the relationship between
the ranks (lower diagonal of the scatterplot matrix) and standard
deviation (upper diagonal of the scatterplot matrix) in the posterior
distributions for the five latent variable models. These figures
illustrate the following. First, inclusion of the odds ratios as a
feature in the BLVM (Model 1) resulted in SNPs with very low
MAF and large effects being ranked in the top SNPs along with
rankings from this model inconsistent with (1) rankings based on
the other four models and (2) rankings based on the p-values from
the case-control association analysis. Second, ranks based on
model 2, 3 and 4 are very consistent with similar SD in rankings.
In terms of variation in ranks, posterior distributions for rankings
of the SNP latent quality score for model 3 had slightly larger
variation as compared to models 2 and 4, with no real difference in
variation in posterior distribution between models 2 and 4. Lastly,
Figure 2. Plot of SNP ranks (mean of posterior distribution of rank) and the 2log10(p-values) from analyses using (A) all invasive
cases or (B) only invasive serous cases for each of the five BLVMs.
doi:10.1371/journal.pone.0020764.g002
Ranking SNPs and Loci for Follow-Up Studies
PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e20764model 5 had lower concordance with model 2, 3 and 4’s rankings
and p-values from the association analysis, but produce smaller
variation in rankings (SD) than models 2, 3 and 4. Based on these
results, we opted to use model 2, which is the simplest BLVM
model, to estimate the SNP latent quality scores for the top 500
markers from chromosome 20.
Ranking of the top 500 SNPs. Based on the results from the
ranking of the top 100 SNPs on chromosome 20 using the five
BLVM, we next used the simplest model (Model 2) to rank the top
500 markers using the features: p-value from case-control analysis
involving all cases, p-value from case-control analysis involving
only cases with serous histology, and the MAF for the marker.
Table 1 presents the top 40 ranked markers based on the BLVM
of 500 markers from chromosome 20, sorted by posterior
probability of being in top 5 markers. Results for all 500
markers are presented in Table S1. The markers were ranked
based on the mean of the posterior distribution for the latent SNP
‘‘quality score’’. The top ranked marker (marker 1) from the
BLVM had a median rank of 6 and was in the top 5 markers 47%
of the time. As the 95% credible interval indicates, there is a large
amount of variation in the rank with the interval ranging from 1 to
302. However, marker 1 was ranked 2
nd and 7
th based on the p-
value from the case-control analysis involving all cases and the
histological subtype analysis, respectively. Similarly, the second
Figure 3. Plots of the mean rank (lower diagonal of sub-plots) and standard deviation in rank (upper diagonal of sub-plots) in the
posterior distributions of the rankings from the five BLVMs. The two set of sub-plots are all plotted on the same scale.
doi:10.1371/journal.pone.0020764.g003
Table 1. Top 40 markers determined from BLVM. The markers are sorted by P(top 5).
Marker MAF Invasive Serous Rank based on P Posterior Dist of Ranks
P OR P OR Invasive Serous P(top 5) Median
1 0.139 2.0E-05 0.82 2.0E-05 0.79 2 7 0.47 6
2 0.14 2.0E-05 0.82 3.0E-05 0.79 1 9 0.46 7
3 0.116 3.0E-05 1.22 1.2E-04 1.26 3 24 0.33 15
4 0.13 4.0E-05 0.82 4.0E-05 0.79 4 13 0.27 12
5 0.134 4.0E-05 0.83 6.0E-05 0.8 7 20 0.19 16
6 0.18 4.0E-05 0.84 8.0E-05 0.82 6 23 0.19 17
7 0.18 4.0E-05 0.84 8.0E-05 0.82 5 21 0.19 17
8 0.11 2.0E-03 1.17 1.0E-05 1.32 197 1 0.13 151
9 0.252 4.0E-05 0.86 3.2E-02 0.91 8 286 0.12 52
10 0.126 7.0E-05 1.21 8.0E-05 1.25 9 22 0.09 21
11 0.015 1.4E-04 0.61 5.0E-05 0.51 41 16 0.06 38
12 0.174 1.0E-04 0.85 1.5E-04 0.82 20 26 0.05 29
13 0.015 1.5E-04 1.64 6.0E-05 1.94 43 19 0.05 40
Ranking SNPs and Loci for Follow-Up Studies
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probability in the top 5 of 0.46, was ranked 1
st and 9
th based on
the analysis of all cases, regardless of histological type, and the
cases with serous histological subtype invasive ovarian cancer. In
contrast, the top ranked marker (marker 8) based on the subtype
analysis p-value (197
th based on the all case analysis) ranked in the
top 5 markers with probability 0.13 based on the BLVM. The
probability of being in the top 5, as opposed to the rank based on
the mean of the posterior distribution of the quality score, takes
into account the variation in rankings. This can also be seen in the
95% credible intervals for the rankings of the markers.
Figure 4 displays the relationship between the various SNP
features and rankings for the 500 markers. As the figure illustrates,
the ranking of markers based on the BLVM is related mostly to the
p-value from the invasive cases analysis and less so from the results
of the invasive serous case analysis and MAF. We also observed
that the probability of being in the top 5 markers is highest for
markers with small p-values for both invasive and invasive serous
analysis is as well as having MAF around 0.10–0.20.
Simulated Data
The BLVM (Model 6) was applied to each of the 10 simulated
datasets, in which the four disease association p-values and the
function (coding or non-coding variant) for the 100 SNP markers
were included in the latent model. The models were fit using the
WinBUGS software package [26] by way of the R package BRugs
[27]. For each analysis, three independent chains were run, each
with 40,000 iterations, with the first 20,000 removed for burn-in of
the MCMC. The mean SNP ‘‘quality score’’ and median rank for
Scenarios 2–4 (non-null scenarios) are presented in Table 2, with
the mean computed for null and non-null markers along with
coding and non-coding markers. Table 3 presents the results for
the null scenario (Scenario 1). As the tables illustrate, for Scenario
2 the median ranking for the non-null marker (a functional
marker) is in the top 4% of markers in 6 out of 10 simulations,
while the average median rank for the null markers was around
50, as expected. When compared to Scenario 3, in which the
associated marker is not a coding marker, the median rank for the
associated markers is much lower than the ranking from Scenario
2, due to the fact that the non-null marker was not a coding
variant. The final scenario in which all four diseases are associated
with a non-coding marker, we observe that the ranking for the
associated marker improve due to the added information from
association with phenotypes 3 and 4. In terms of the null scenario
(Scenario 1), the coding markers are ranked slightly higher than
the non-coding markers due to BLVM putting some importance
on coding variants over non-coding variants (Table 3).
Marker MAF Invasive Serous Rank based on P Posterior Dist of Ranks
P OR P OR Invasive Serous P(top 5) Median
14 0.049 8.0E-05 0.75 1.5E-03 0.76 10 57 0.04 45
15 0.049 8.0E-05 1.32 1.5E-03 1.31 11 58 0.04 45
16 0.049 8.0E-05 0.75 1.5E-03 0.76 13 59 0.04 45
17 0.049 8.0E-05 1.32 1.5E-03 1.32 12 60 0.04 46
18 0.258 9.0E-05 0.87 3.9E-02 0.91 15 301 0.02 74
19 0.258 9.0E-05 1.15 3.8E-02 1.1 16 297 0.02 75
20 0.258 9.0E-05 0.87 3.8E-02 0.91 17 298 0.02 75
21 0.258 9.0E-05 0.87 3.8E-02 0.91 18 300 0.02 75
22 0.259 9.0E-05 0.87 4.3E-02 0.91 14 311 0.02 73
23 0.258 1.0E-04 1.15 4.1E-02 1.09 19 307 0.02 76
24 0.257 1.1E-04 1.15 3.8E-02 1.1 24 296 0.02 79
25 0.258 1.1E-04 1.15 4.4E-02 1.09 21 321 0.02 80
26 0.258 1.1E-04 1.15 4.4E-02 1.09 22 319 0.02 80
27 0.258 1.1E-04 0.87 4.3E-02 0.91 25 318 0.02 81
28 0.258 1.1E-04 1.15 4.4E-02 1.09 23 320 0.02 81
29 0.258 1.1E-04 0.87 4.3E-02 0.91 26 317 0.02 81
30 0.258 1.1E-04 0.87 4.5E-02 0.91 28 329 0.02 81
31 0.258 1.1E-04 1.15 4.4E-02 1.09 30 322 0.02 81
32 0.258 1.1E-04 0.87 4.5E-02 0.91 27 327 0.02 82
33 0.258 1.1E-04 1.15 4.4E-02 1.09 31 323 0.02 82
34 0.147 4.6E-04 1.17 8.2E-04 1.2 67 37 0.01 77
35 0.125 5.9E-04 0.84 8.4E-04 0.81 81 40 0.01 89
36 0.176 1.4E-04 0.85 1.2E-02 0.88 40 218 0.01 78
37 0.002 2.2E-04 0.24 4.0E-03 0.24 53 119 0.01 85
38 0.038 7.6E-04 1.35 5.0E-04 1.44 90 34 0.01 102
39 0.434 3.4E-04 0.89 6.8E-03 0.9 57 186 0.01 96
40 0.434 3.5E-04 0.89 6.8E-03 0.9 59 185 0.01 96
doi:10.1371/journal.pone.0020764.t001
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Over the past few years, numerous GWAS for various complex
disease and drug-related phenotypes have been completed,
resulting in more than 350 publications and over 1500 SNPs
implicated for association with multiple (.80) disease phenotypes
or traits [1]. However, the SNPs identified are not necessarily the
functional variant, requiring additional research to fine map these
putative regions or loci [28] for further biological characterization.
Given the extensive efforts involved, it is important to prioritize
SNPs for functional studies detected from GWAS. We propose a
Bayesian latent variable model (BLVM) to assist in this process.
The BLVM allows researchers to incorporate various ‘‘features’’
about the SNP into the ranking, including results from analysis of
multiple phenotypes and prior knowledge, such as whether or not
the SNP is a non-synonymous variant or associated with mRNA
expression (eSNP) [22,23]. In addition, the BLVM allows one to
quantify the uncertainty in the ranking by estimating the
probability that the SNP will be in the top K SNPs. The proposed
Bayesian latent variable model (BLVM) incorporates these SNP
‘‘features’’ to estimate a latent ‘‘quality score’’, with SNPs
prioritized based on the posterior probability distribution of the
quality score rankings. We illustrate the method using data from
an ovarian cancer GWAS of 1815 cases (1070 serous subtype) and
1900 controls, and compare the results from the BLVM to the
standard ranking of SNPs based on the association p-value. In
addition to the application of the BLVM to the ovarian GWAS,
we outlined five BLVM models and compared the rankings from
these five models. In the end, we opted for the BLVM simplest
model for the ranking of SNPs for prioritization for functional
studies. Results from the BLVM applied to the ovarian GWAS
results for chromosome 20 indicate that if there is only resources to
functionally validate a few markers, one should select the two
markers with posterior probability of being in the top 5 markers of
0.46. However, for this study, the same two SNPs are selected for
follow-up based on the p-value rankings from the analysis of
invasive ovarian cancer and controls. In addition, depending on
whether the follow-up involves replication of the association, as
opposed to completion of functional studies, selection of only one
of these two markers is necessary, as they are in high LD.
Figure 4. Relationship between SNP association p-values, rankings based on p-values and BLVM and Probability in the top 5
markers. I.P and S.P represent the p-values from the analyses involving all invasive cases or invasive serous cases, respectively; I.P.Rank and S.P.Rank
represent the rank of the marker based on the p-values from the analysis involving all invasive cases or invasive serous cases, respectively; BLVM.Rank
and P.Top5 represent the median rank and the probability of being in the top 5 markers based on the BLVM.
doi:10.1371/journal.pone.0020764.g004
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integrate multiple features about the SNPs, the model is flexible in
terms of model choice, choice of features to incorporate into the
prioritization and weight/importance given to the different
features. For example, in the simulated data, we illustrate the
use of the BLVM for synthesizing results from multiple genetic
association studies conducted on related diseases/traits, as a means
for detecting pleiotropic effects (e.g., genetic variants associated
with multiple traits). In the application of the BLVM to the
simulated data, we also incorporated information regarding
whether or not the marker was a coding SNP. The results showed
how the inclusion of knowledge about the ‘‘functional’’ aspect of
the SNP impacted the results, along with the effect of having all
four traits associated with the marker, as compared to only two
traits. The application of the BLVM to both the ovarian GWAS
and the simulated data, further illustrates the flexibly in model
choice and which features to include in the model. For instance,
imputation of untyped markers for association analysis in GWAS
is becoming a commonly used analysis technique [29,30,31].
However, researchers may wish to prioritize observed SNPs over
imputed SNPs. This information, or feature, can be included in
the model such that SNPs genotyped will be given more weight
than SNPs imputed based on a reference panel (e.g., HapMap).
Lastly, sensitivity analysis is possible (and recommended) to
assess the impact of modeling choice on the results, as illustrated
with the comparison of the five BLVM and the ovarian cancer
GWAS. Currently, there is a limitation on the number of markers
one can model with BLVM, due to the computational nature of
the Bayesian model (i.e., only a few thousand SNPs). Thus,
following the genome-wide analysis, a couple thousand markers
Table 2. Summary of simulated p-values and results from analysis using BLVM for Scenarios 2, 3 and 4.
Simulation* Mean Quality Score Median Rank Mean Quality Score Median Rank
Scenario 2 Null Non-Null Null Non-Null Non-Coding Coding Non-Coding Coding
1 20.029 2.46 50.69 1 20.052 1.57 51.5 7.3
2 20.018 1.64 50.95 4 20.033 1.01 51.5 17.7
3 20.021 1.81 50.77 3 20.038 1.12 51.4 13.7
4 20.023 2.1 51.36 1 20.037 1.12 51.8 21
5 20.02 1.73 50.83 4 20.041 1.24 51.6 11
6 20.02 2.08 51.11 2 20.043 1.41 51.8 14
7 20.016 1.33 50.77 7 20.027 0.8 51.1 25
8 20.029 2.81 50.9 1 20.064 2.05 51.8 4.7
9 20.022 2.21 51.06 2 20.04 1.32 51.6 16.3
10 20.023 2.36 50.82 2 20.053 1.73 51.6 10.3
Scenario 3
1 20.011 0.84 50.82 20 20.022 0.64 51.3 26.3
2 20.005 0.19 50.91 51 20.039 1.15 52.1 11.3
3 20.009 0.6 50.65 25 20.033 0.97 51.4 16.7
4 20.006 0.48 50.28 38 20.037 1.16 51.3 13
5 20.025 2.1 51.13 3 20.004 20.01 50.7 48.7
6 20.012 0.74 50.78 26 20.034 0.95 51.4 21
7 20.003 0.26 50.77 42 20.044 1.39 52 7
8 0.002 20.19 50.2 63 20.046 1.47 51.6 7.7
9 20.008 0.66 50.71 23 20.031 0.96 51.4 19
10 20.004 0.72 50.92 24 20.011 0.47 51.1 36.7
Scenario 4
1 20.018 1.86 50.76 3 20.009 0.33 50.8 35
2 20.017 1.53 50.88 5 20.026 0.79 51.2 24.7
3 20.021 1.85 51.25 2 20.024 0.7 51.4 29
4 20.018 1.91 50.78 3 20.021 0.72 51.2 21.3
5 20.02 1.91 51.19 3 20.014 0.43 51.1 39.7
6 20.017 1.54 50.65 6 20.008 0.19 50.4 42.3
7 20.023 2.07 51.01 3 20.005 0.08 50.7 45
8 20.02 1.75 50.97 4 20.026 0.77 51.4 22.3
9 20.038 3.54 51.06 1 20.004 0.07 50.8 44.3
10 20.013 1.27 50.48 9 20.032 1.04 51.1 16.7
*Scenario 2: SNP 10 (coding SNP) simulated to be associated with phenotypes 1 & 2.
Scenario 3: SNP 60 (non-coding SNP) simulated to be associated with phenotypes 1 & 2.
Scenario 4: SNP 60 (non-coding SNP) simulated to be associated with all phenotypes.
doi:10.1371/journal.pone.0020764.t002
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values or q-values) for which BLVM can be applied using SNP
‘‘features’’ the investigator feels are important in the prioritization,
to determine which markers to carry forward into follow-up
studies. Another possible approach to reduce the model space
would be to remove SNPs in high LD prior to analysis using the
BLVM. However, as this approach might be acceptable for follow-
up studies involving replication, it might not be an appropriate
approach for selecting SNPs for functional studies as one could be
removing functional variants in high LD with non-functional
variants. Future work is needed to determine the optimal
approach to deal with markers in high LD and algorithms to
speed up the computation time of the BLVM. In summary, the
BLVM is a flexible model that allows for the systematic integration
of multiple SNP features, along with the ability to assess the
uncertainty in the ranking, for the prioritization of markers for
future functional studies.
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